Key result
Anthracycline-induced cardiotoxicity limits clinical utility and drives development of liposomal and nanoparticle formulations.
Anthracyclines are a clinically important class of antineoplastic agents whose use is limited by cumulative dose-dependent cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor cumulative anthracycline doses to limit cardiotoxicity; leaves open comparative outcomes of liposomal formulations in prospective trials.
Anthracyclines are a clinically important class of antineoplastic agents used to treat a wide variety of solid and blood cancers.The first described anthracycline, daunorubicin, was first isolated from a strain of Streptomyces peucetius in the early 1960s.Clinically the most widely used are doxorubicin, daunorubicin and their semisynthetic derivatives epirubicin and idarubicin.They primarily act by intercalating with DNA and inhibiting topoisomerase II, resulting in DNA breaks and abrogated DNA synthesis.The most serious side effect of anthracycline use is cumulative dose-dependent cardiotoxicity, limiting recommended maximum lifetime treatment to 400-450 mg/m2.Several liposomal formulations of doxorubicin are in use, having the benefits of prolonging retention rate while reducing peak plasma concentration of free drug.Several clinical trials of anthracycline-loaded nanoparticles are currently underway.
No takes yet. Share an insight, caveat, or question.
Cheong et al. (2018) conducted a review in Cancer. Anthracyclines was evaluated. Anthracyclines are effective antineoplastic agents whose clinical utility is limited by cumulative dose-dependent cardiotoxicity, prompting the development of liposomal and nanoparticle formulations.
Synapse has enriched 10 related papers. Consider them for comparative context: